COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split")
Zomedica Corp. (NYSE American:ZOM), a veterinary health company, announced a record revenue for the fourth quarter of 2023 and full year 2023, driven by strong performance across its product lines. The company expects to continue its growth momentum in 2024 with the introduction of formal financial guidance. Additionally, Zomedica will be seeking approval for an 80-1 reverse stock split to generate long-term shareholder value. The Company will be hosting a conference call to provide more details on its business update on Wednesday, January 17, 2024, at 4:30 p.m. Eastern Time. -
COMMUNIQUÉ DE PRESSE
Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of Sharehol
Zomedica Corp., a veterinary health company, will host a conference call on January 17, 2024, to provide a business update, including 2023 revenue and cash position, and discuss the upcoming Share Consolidation and Special Virtual-Only Meeting of Shareholders. For more information and to join the call, visit zomedica.com. -
COMMUNIQUÉ DE PRESSE
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
Zomedica Corp. announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients without sedation. The article describes the use of a novel shockwave trode, reinforcing current clinical evidence on the effectiveness of electro-hydraulic shock wave therapy for various indications. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available on Frontiers in Veterinary Science. In addition, CSU is evaluating PulseVet therapy for slowing the progression of canine osteoarthritis, with expected results later in 2024. The ability to treat patients without sedation using X-Trode is seen as a major advancement. Zomedica's Vice President of Clinical and Veterinary Affairs, Adrian Lock, expressed excitement for the upcoming study to further validate the therapy's efficacy. The company's CEO, Larry Heaton, believes the publication will accelerate the acceptance of shock wave therapy for small animal patients. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells, promoting healing growth factors. Zomedica's commitment to advancing veterinary care is evident through ongoing clinical studies and product innovations. The company's mission to address the unmet needs of clinical veterinarians underscores its dedication to animal welfare and better veterinary practice. For more information, readers can visit Zomedica's website. -
-
COMMUNIQUÉ DE PRESSE
Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners
Zomedica announces presentation of clinical data in support of new indications for Pulsevet shock wave therapy at annual meeting of American Association of Equine Practitioners -
-
COMMUNIQUÉ DE PRESSE
Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
-
-
